Quest Diagnostics: Interpretive Guide

Documents above are in PDF Format, if you do not have Acrobat Reader, you may download the latest version from Adobe's site.




Welcome to the Interpretive Guide. This Guide provides information relating to test selection, utilization, and interpretation. The Guide is continually updated by adding new information and modifying posted information. All information is based on peer-reviewed publications, practice guidelines, or other reputable sources and is intended to be without promotional considerations.

Reference ranges are provided for your convenience and are based on Quest Diagnostics data or published references (where cited). These ranges can serve as a guideline; however, interpretation of patient results should be based on the ranges provided in the patient report.

Included in the Interpretive Guide are four types of information:

•	Test highlights and summaries provide a review of clinical use and background, methodology, specimen requirements, and interpretation of the test.

•	Test guides provide testing algorithms or other information that assists in appropriate test selection.

•	Technology guides compare multiple technologies provided for the same or similar analytes.

•	Clinical focus pages focus on specific diseases or conditions, providing detailed information on what tests are available, how they are incorporated into clinical practice, and what the results mean.

What's New

•	The Genomic Alterations, Oncology, Clarisure^® CGH test uses microarray comparative genomic hybridization (CGH) technology to detect genetic gains and losses throughout the genome. Clinically, it is used as an adjunct to karyotyping and fluorescence in situ hybridization (FISH) for detecting chromosome abnormalities that may have prognostic significance for patients with hematologic malignancies.
•	The ColoVantage™ (methylated Septin 9) test detects circulating methylated DNA from the SEPT9 gene. Such methylated DNA has been associated with colorectal cancer.
•	The Inflammatory Bowel Disease Differentiation Panel may be helpful in differentiating between ulcerative colitis (UC) and Crohn disease (CD) in some patients with inflammatory bowel disease (IBD).
•	The Antithrombotic Therapy clinical focus provides laboratory test selection and interpretive information to facilitate optimal drug dosing and therapeutic monitoring of 5 common antithrombotic therapies.